Please assess the completion status of the following clinical trial:

Trial Title: Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made~* Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled~* Prior/current treatment with any anti-VEGF intravitreal injections or macular laser (laser and/or visudyne/PDT) in the fellow eye is allowed~* Man or woman aged 18 years or more~* Patient who has been given appropriate information about the study objectives and procedures and who has given his/her written, informed consent;~Exclusion Criteria:~* Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks~* Patient who does not meet the local indication criteria for Eylea treatment.Contraindications listed in the Summary of Product Characteristics (SmPC) must be taken into account~* Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye~* Patient taking part in an interventional study at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): According to the recommendations of the Summary of Product Characteristics (SmPC)

Based on this trial design, predict the completion outcome and termination type (if applicable).